Ads
related to: Skyrizi- Treatment FAQs
Get Answers To Frequently Asked
Questions About Our Treatment.
- Explore Savings Options
Sign Up For Information, Updates,
& A $0 Co-Pay Savings Offer.
- Treatment Cost Info
Find Information On Paying For
Our Psoriatic Arthritis Treatment.
- Discussion Guide
Questions To Ask Before Seeing Your
Doctor To Talk About Treatment.
- Treatment FAQs
Search results
AbbVie: An Undervalued Giant
GuruFocus.com via Yahoo Finance· 1 day agoAbbVie's resilience: Surging beyond Humira with sky-high Skyrizi and Rinvoq revenue Revenue in the fourth quarter of 2023 was $14.3 billion, representing...
Long Live the Dividend Kings: 3 Top Picks to Build an Income Portfolio
InvestorPlace· 13 hours agoWhether an investor seeks steady income or long-term growth, the dividend king stocks are a great...
AbbVie (ABBV) to Buy Landos to Strengthen Autoimmune Portfolio
Zacks via Yahoo Finance· 2 days agoThe deal will strengthen AbbVie’s inflammatory and autoimmune disease portfolio, which includes...
AbbVie to bolster immunity illness drug pipeline with Landos deal
Reuters via AOL· 3 days agoLandos is currently conducting a mid-stage study of its lead experimental drug NX-13 in a type of an...
AbbVie keeps up acquisition spree, this time for an immunology-focused startup
Crain s Chicago Business· 3 days agoVirginia-based Landos has a Phase 2 clinical trial underway for NX-13, a drug for treating ulcerative colitis, the release said. The oral therapeutic could provide a novel approach to fighting ...
AbbVie to buy immune drug developer Landos
BioPharma Dive via Yahoo Finance· 3 days agoAbbVie already sells two blockbuster drugs that can treat types of IBD: Rinvoq, approved for ulcerative colitis and Crohn’s, and Skyrizi, which is only...
Gastroenterologists Slow to Adopt Eli Lilly’s Omvoh, Pfizer’s Velsipity, and Takeda’s subcutaneous...
Morningstar· 6 days agoAmong them is Eli Lilly’s Omvoh (mirikizumab), the first FDA approved IL-23 inhibitor for UC, Pfizer’s Velsipity (etrasimod), the second Sphingosine-1 phosphate (S1P) receptor-modulator, as ...
These stocks may have trouble living up to expectations for a big earnings turnaround this year
CNBC· 2 days agoAnalysts are predicting a major bounce back in earnings for several companies in the S & P 500 this...
Council Post: What's Driving Big Pharma's Recent Market Performance?
Forbes· 4 days agoThe financial performance of major pharmaceutical companies highlights the divergent trajectories of...
‘Awful’: Internet says as ‘Teen Mom’ star Kayla Sessler reveals third baby's name on social media
MEAWW· 2 days agoLOS ANGELES, CALIFORNIA: Kayla Sessler well-known for her appearance on the reality TV show 'Teen...
Ads
related to: Skyrizi